Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. It operates through two segments, Life Sciences and Animal Health. The company's custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development. In addition, it provides tools and contract services to assist the diagnosis of conditions in animals to enable treatment for veterinarians. The company has a collaboration, licensing, and option agreement with Moderna Therapeutics; research collaboration with OncoSec Medical Incorporated for gene delivery of therapeutic Affimers; and a co-development partnership agreement with Bach Biosciences LLP to develop Affimer drug conjugate therapies. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
Industry, Sector and Symbol
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
Phone+44-1904-217070
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees114
OptionableNot Optionable
Avacta Group (LON:AVCT) Frequently Asked Questions
What is Avacta Group's stock symbol?
Avacta Group trades on the London Stock Exchange (LON) under the ticker symbol "AVCT."
What price target have analysts set for AVCT?
0 brokers have issued 1 year target prices for Avacta Group's stock. Their predictions range from GBX 200 to GBX 200. On average, they expect Avacta Group's stock price to reach GBX 200 in the next twelve months. This suggests a possible upside of 360.8% from the stock's current price. View Analyst Price Targets for Avacta Group.
Has Avacta Group been receiving favorable news coverage?
Media stories about AVCT stock have trended very positive this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Avacta Group earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are some of Avacta Group's key competitors?
Some companies that are related to Avacta Group include Activecare (ACAR), Advanced Oncotherapy (AVO), Airware Labs (AIRW), Anteo Diagnostics (ADO), Aurora Spine (ASG), Azure Healthcare (AZV), Cannabix Technologies (BLOZF), Cochlear (COH), ConvaTec Group (CTEC), Creo Medical Group (CREO), Draegerwerk AG & Co KGaA (DRW3), Electromed (ELMD), Ellex Medical Lasers (ELXMF), EMvision Medical Devices (EMV) and Fisher & Paykel Healthcare (FPH).
Who are Avacta Group's key executives?
Avacta Group's management team includes the folowing people:
- Prof. Alastair Smith, CEO & Exec. Director
- Mr. Tony Gardiner, CFO, Company Sec. & Exec. Director (Age 47)
- Dr. Michael Albin, Adviser
- Dr. Matt Johnson, Chief Technology Officer
- Dr. Amrik Basran Ph.D., Chief Scientific Officer
How do I buy shares of Avacta Group?
Shares of AVCT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Avacta Group's stock price today?
One share of AVCT stock can currently be purchased for approximately GBX 43.40.
What is Avacta Group's official website?
How can I contact Avacta Group?
Avacta Group's mailing address is Unit 20, Ash Way, WETHERBY, LS23 7FA, United Kingdom. The biotechnology company can be reached via phone at +44-1904-217070.
MarketBeat Community Rating for Avacta Group (LON AVCT)
MarketBeat's community ratings are surveys of what our community members think about Avacta Group and other stocks. Vote "Outperform" if you believe AVCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVCT will underperform the S&P 500 over the long term. You may vote once every thirty days.
